The effect of FDA advisories on branded pharmacetical firms: valuations and promotion efforts
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Cambridge, Mass.
National Bureau of Economic Research
2011
|
| Schriftenreihe: | NBER working paper series
17528 |
| Beschreibung: | 25 S. graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV039712779 | ||
| 003 | DE-604 | ||
| 005 | 20120313 | ||
| 007 | t | ||
| 008 | 111119s2011 d||| |||| 00||| eng d | ||
| 035 | |a (DE-599)BVBBV039712779 | ||
| 040 | |a DE-604 |b ger | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-M382 | ||
| 100 | 1 | |a Conti, Rena M. |e Verfasser |0 (DE-588)131907573 |4 aut | |
| 245 | 1 | 0 | |a The effect of FDA advisories on branded pharmacetical firms |b valuations and promotion efforts |c Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt |
| 264 | 1 | |a Cambridge, Mass. |b National Bureau of Economic Research |c 2011 | |
| 300 | |a 25 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a NBER working paper series |v 17528 | |
| 700 | 1 | |a Huskamp, Haiden A. |e Verfasser |0 (DE-588)171901215 |4 aut | |
| 700 | 1 | |a Berndt, Ernst R. |e Verfasser |0 (DE-588)128550783 |4 aut | |
| 830 | 0 | |a NBER working paper series |v 17528 |w (DE-604)BV002801238 |9 17528 | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-024561090 | ||
Datensatz im Suchindex
| _version_ | 1804148588447531008 |
|---|---|
| any_adam_object | |
| author | Conti, Rena M. Huskamp, Haiden A. Berndt, Ernst R. |
| author_GND | (DE-588)131907573 (DE-588)171901215 (DE-588)128550783 |
| author_facet | Conti, Rena M. Huskamp, Haiden A. Berndt, Ernst R. |
| author_role | aut aut aut |
| author_sort | Conti, Rena M. |
| author_variant | r m c rm rmc h a h ha hah e r b er erb |
| building | Verbundindex |
| bvnumber | BV039712779 |
| ctrlnum | (DE-599)BVBBV039712779 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01031nam a2200277 cb4500</leader><controlfield tag="001">BV039712779</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20120313 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">111119s2011 d||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV039712779</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-M382</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Conti, Rena M.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)131907573</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The effect of FDA advisories on branded pharmacetical firms</subfield><subfield code="b">valuations and promotion efforts</subfield><subfield code="c">Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Cambridge, Mass.</subfield><subfield code="b">National Bureau of Economic Research</subfield><subfield code="c">2011</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">25 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">NBER working paper series</subfield><subfield code="v">17528</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Huskamp, Haiden A.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)171901215</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berndt, Ernst R.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)128550783</subfield><subfield code="4">aut</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">NBER working paper series</subfield><subfield code="v">17528</subfield><subfield code="w">(DE-604)BV002801238</subfield><subfield code="9">17528</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-024561090</subfield></datafield></record></collection> |
| id | DE-604.BV039712779 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T00:09:31Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-024561090 |
| open_access_boolean | |
| owner | DE-M382 |
| owner_facet | DE-M382 |
| physical | 25 S. graph. Darst. |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | National Bureau of Economic Research |
| record_format | marc |
| series | NBER working paper series |
| series2 | NBER working paper series |
| spelling | Conti, Rena M. Verfasser (DE-588)131907573 aut The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt Cambridge, Mass. National Bureau of Economic Research 2011 25 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier NBER working paper series 17528 Huskamp, Haiden A. Verfasser (DE-588)171901215 aut Berndt, Ernst R. Verfasser (DE-588)128550783 aut NBER working paper series 17528 (DE-604)BV002801238 17528 |
| spellingShingle | Conti, Rena M. Huskamp, Haiden A. Berndt, Ernst R. The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts NBER working paper series |
| title | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts |
| title_auth | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts |
| title_exact_search | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts |
| title_full | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt |
| title_fullStr | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt |
| title_full_unstemmed | The effect of FDA advisories on branded pharmacetical firms valuations and promotion efforts Rena M. Conti ; Haiden A. Huskamp ; Ernst R. Berndt |
| title_short | The effect of FDA advisories on branded pharmacetical firms |
| title_sort | the effect of fda advisories on branded pharmacetical firms valuations and promotion efforts |
| title_sub | valuations and promotion efforts |
| volume_link | (DE-604)BV002801238 |
| work_keys_str_mv | AT contirenam theeffectoffdaadvisoriesonbrandedpharmaceticalfirmsvaluationsandpromotionefforts AT huskamphaidena theeffectoffdaadvisoriesonbrandedpharmaceticalfirmsvaluationsandpromotionefforts AT berndternstr theeffectoffdaadvisoriesonbrandedpharmaceticalfirmsvaluationsandpromotionefforts |